Post by PharmaShots

🚨 𝐀 𝐍𝐞𝐰 𝐄𝐫𝐚 𝐢𝐧 𝐀𝐬𝐭𝐡𝐦𝐚 𝐂𝐚𝐫𝐞 𝐁𝐞𝐠𝐢𝐧𝐬 What does the first FDA-approved fixed-dose triple-combination maintenance therapy for asthma mean for patients, physicians, and the future of respiratory medicine? In this exclusive PharmaShots ViewPoints, industry leaders from AstraZeneca share how Breztri Aerosphere's US approval is poised to reshape asthma treatment and expand the role of single-inhaler triple therapy. 🎙️ Featuring: • Caterina Brindicci – Senior Vice President & Global Head, R&D, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca • James Teague – Vice President, US Respiratory & Immunology and Vaccine & Immune Therapies, AstraZeneca The conversation explores: 🔹 The significance of Breztri's landmark US approval 🔹 How triple therapy could redefine the standard of care for uncontrolled asthma 🔹 AstraZeneca's long-term vision for respiratory disease—from symptom control to disease modification 🔹 The future of global access as regulatory reviews continue across the EU, Japan, and China As respiratory care continues to evolve, this discussion offers valuable insights into one of the most significant advances in asthma management in recent years. 📖 Read the full ViewPoints interview and discover how innovation is transforming respiratory healthcare. #PharmaShots #ViewPoints #AstraZeneca #BreztriAerosphere #Asthma #AsthmaCare #TripleTherapy #Respiratory #COPD #FDAApproval #RespiratoryMedicine #Biopharma #HealthcareInnovation #LifeSciences #Pharmaceuticals